DJIA 16,408.54 -16.31 -0.10%
NASDAQ 4,095.52 0.00 0.00%
S&P 500 1,864.85 2.54 0.14%
market minute promo

Hospira, Inc.

NYSE: HSP



company name or ticker
Company Photos
(Click to zoom)

Ariel Capital's John Rogers Trims Sotheby's, DeVry, Hospira, IPG, Others

Ariel Capital's John Rogers Trims Sotheby's, DeVry, Hospira, IPG, Others

Ariel Capital's John Rogers Trims Sotheby's, DeVry, Hospira, IPG, Others

Top 4 Stocks In The Drug Delivery Industry With The Lowest PEG Ratio

Hospira Incorporated: Unappreciated Upside Due To A Promising Biosimilar Pipeline

Hospira Becomes #21 Most Shorted S&P 500 Component, Replacing Sigma-Aldrich

Five Companies Cut - Pzena Investment Management Update

Five Companies Cut - Pzena Investment Management Update

Will Biosimilars Unlock This Company's Long-Term Potential?

Hospira has faced some major problems in its medical devices business after a damaging FDA ban. However, many investors are overlooking the company’s long-term growth potential in biosimilars.

Earnings Beat at Hospira in Q3, View maintained - Analyst Blog

Hospira Management Discusses Q3 2013 Results - Earnings Call Transcript

Tesla plunges on outlook; A&F loses its cool

See More Articles...